GSK invests $120M in biopharma plant as renewed oncology bets grow

GlaxoSmithKline has a pipeline bulging with oncology bets as it moves forcefully into an area it had let drop off its radar screen. Today, the drugmaker opened a $120 million biologics plant to handle them as they come to fruition.